Form 4: Revolution Medicines CFO Sells Shares After Option Exercise

Revolution Medicines CFO Jack Anders exercised stock options and immediately sold the acquired shares under a pre-arranged 10b5-1 plan.

Summary

• Jack Anders, Chief Financial Officer of Revolution Medicines, Inc. (RVMD), reported transactions on November 25, 2025.
• Anders exercised 5,418 stock options at an exercise price of $17 per share.
• Concurrently, Anders sold 5,418 shares of common stock at a price of $74 per share.
• These transactions were executed pursuant to a Rule 10b5-1 trading plan adopted on December 16, 2024.
• Following these transactions, Anders beneficially owns 110,994 shares of common stock, which includes 48,275 restricted stock units.
• No derivative securities (stock options) are beneficially owned after the reported transactions.

Sentiment

Score: 5

Explanation: Neutral, as this is a routine disclosure of an insider transaction under a pre-arranged trading plan, not indicative of company performance or future prospects.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This filing is a routine disclosure of an insider's transaction and does not provide information directly related to broader industry trends or competitive landscape.

Stakeholder Impact

• Shareholders: Disclosure of insider selling, which can sometimes be perceived negatively, though mitigated by the fact it was executed under a pre-arranged 10b5-1 plan, indicating it was not based on new, non-public information.

Key Dates

Keywords

Revolution Medicines, RVMD, Jack Anders, CFO, Insider Trading, Form 4, Stock Option Exercise, Stock Sale, 10b5-1 Plan